InMed Pharmaceuticals Reports Q1 FY2027 Results, Updates Mentari Merger and Nasdaq Compliance

What happened

InMed Pharmaceuticals reported a $2.33 million net loss for the first quarter of fiscal 2027. Its proposed merger with Mentari is expected to close in the fourth quarter of 2026, subject to remaining conditions including shareholder approvals, and is not yet final.

Proposed

Global impact / market context

A $2.33 million quarterly loss and cash falling to $1.0 million mean InMed must control spending carefully, because its cash is expected to last only into mid-November. The proposed merger could change that outlook if it closes.

Analyst inference

InMed also received Nasdaq's acceptance of its plan to meet the minimum shareholders' equity requirement by March 15, 2027. That is a listing rule about the company's net worth, so failing to comply could threaten its place on the exchange.

Analyst inference

What to watch

1. InMed said its cash is expected to fund operations only into mid-November, so watch whether it raises more money or cuts costs before then. Confirmed
2. Watch whether shareholders approve the proposed Mentari merger and whether the remaining conditions are met for an expected close in the fourth quarter of 2026. Proposed
3. Watch InMed's progress toward meeting Nasdaq's minimum shareholders' equity requirement by March 15, 2027, since missing it could affect how easily investors buy and sell the stock. Analyst inference

Evidence

• Original source link unavailable